New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
14:09 EDTPRGO, TEVA, RDY, VRXSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Indian drugmaker Sun Pharmaceutical will buy another Indian pharmaceutical company, Ranbaxy, for $3.2B, the companies said earlier today. Ranbaxy specializes in developing generic drugs. WHAT'S NEW: Sun will buy Ranbaxy in an all-stock transaction via which Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for each share of Ranbaxy. The transaction price represents a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price, the companies stated The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India, the companies noted. WHAT'S NOTABLE: It came to light late last week that another generic drug maker, Mylan (MYL), attempted to buy a Swedish rival, Meda. Meda's board of directors confirmed on Friday that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." OTHERS TO WATCH: Other generic drug makers include Teva (TEVA), Valeant (VRX), Dr. Reddy’s (RDY), and Perrigo (PRGO). PRICE ACTION: In mid-afternoon trading, Mylan fell 3% and Valeant slid over 4%, while Teva, Dr. Reddy's and Perrigo all retreated about 2%.
News For TEVA;VRX;RDY;PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2015
16:22 EDTTEVA, PRGOOn The Fly: Closing Wrap
Subscribe for More Information
15:27 EDTPRGOMylan hasn't made compelling case for Perrigo adding value, says BMO Capital
Subscribe for More Information
15:16 EDTPRGOPerrigo not likely interested in a Mylan deal, says BMO Capital
14:23 EDTTEVA, PRGOAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTPRGO, TEVAMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
13:03 EDTPRGOPerrigo says board will meet to discuss Mylan proposal
Subscribe for More Information
12:37 EDTTEVATeva downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
12:17 EDTRDY, VRX, PRGOOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTPRGOPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTPRGOMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTPRGOPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTPRGOPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
08:56 EDTPRGOPerrigo's ANDA for equivalent of Mallinckrodt's Exalgo approved by FDA
Subscribe for More Information
07:16 EDTTEVAMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
05:10 EDTRDYDr. Reddy's Labs files three NDAs with FDA
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, announced the filing of three 505(b)(2) New Drug Applications, or NDAs, with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology. DFD-01 and DFD-09 are the first dermatology applications submitted to the NDA that have been fully developed leveraging in-house capabilities. DFD-01 is a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from psoriasis. DFD-09 is a modified release oral tetracycline intended for the treatment of rosacea. DFN-11 is the first development program filed in support of a newly created vertical, focused on the U.S. neurology market. DFN-11 is a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens.
April 7, 2015
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use